Compass Therapeutics (CMPX) Non-Current Debt (2019 - 2020)
Compass Therapeutics (CMPX) posted Non-Current Debt of $1.9 million for Q4 2020, down 49.95% sequentially from $3.7 million in Q3 2020, and down 79.91% YoY from $9.3 million in Q1 2020.
Powered by 
Analysis
Compass Therapeutics (CMPX) Non-Current Debt (2019 - 2020) Analysis & Trends
Compass Therapeutics has reported Non-Current Debt for 2 years, with the latest figure at $1.9 million in Q4 2020.
- Quarterly Non-Current Debt fell 79.91% year-over-year to $1.9 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $1.9 million (down 79.91% YoY) and the FY2020 annual result came in at $1.9 million, down 79.91% from the prior year.
- Non-Current Debt declined to $1.9 million in Q4 2020 per CMPX's latest filing, from $3.7 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $9.3 million in Q4 2019 and troughed at $1.9 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 882.16 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 8.96 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Compass Therapeutics | 442.72 Mn | 442.72 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 1.87 Mn |
| Sep 30, 2020 | 3.73 Mn |
| Jun 30, 2020 | 5.59 Mn |
| Dec 31, 2019 | 9.29 Mn |